Publications by authors named "S Goelz"

Progressive multifocal leukoencephalopathy (PML) has been associated with different forms of immune compromise. This study analyzes the chemokine signals and attracted immune cells in cerebrospinal fluid (CSF) during PML to define immune cell subpopulations relevant for the PML immune response. In addition to chemokines that indicate a general state of inflammation, like CCL5 and CXCL10, the CSF of PML patients specifically contains CCL2 and CCL4.

View Article and Find Full Text PDF
Article Synopsis
  • - Natalizumab is a treatment for relapsing multiple sclerosis (MS) but increases the risk of a serious brain infection called progressive multifocal leukoencephalopathy (PML), and researchers explored if detecting JCV-DNA in stool could help assess this risk.
  • - A study of 30 MS patients on natalizumab found JCV-DNA in urine samples of four patients but none in stool or blood, and all viral isolates were of the wild-type without variants associated with PML.
  • - The study concluded that stool samples are not useful for assessing PML risk, suggesting that further research is necessary to understand where harmful JCV variants come from.
View Article and Find Full Text PDF

Progressive multifocal leukoencephalopathy is a crimpling demyelinating disease of the central nervous system caused by JC polyomavirus (JCPyV). Much about JCPyV propagation in the brain remains obscure because of a lack of proper animal models to study the virus in the context of the disease, thus hampering efforts toward the development of new antiviral strategies. Here, having established a robust and representative model of JCPyV infection in human-induced pluripotent stem cell-derived astrocytes, we are able to fully characterize the effect of JCPyV on the biology of the cells and show that the proteomic signature observed for JCPyV-infected astrocytes is extended to extracellular vesicles (EVs).

View Article and Find Full Text PDF

Introduction: The humanized anti-α4 integrin blocking antibody natalizumab (NTZ) is an effective treatment for relapsing-remitting multiple sclerosis (RRMS) that is associated with the risk of progressive multifocal leukoencephalopathy (PML). While extended interval dosing (EID) of NTZ reduces the risk for PML, the minimal dose of NTZ required to maintain its therapeutic efficacy remains unknown.

Objective: Here we aimed to identify the minimal NTZ concentration required to inhibit the arrest of human effector/memory CD4 T cell subsets or of PBMCs to the blood-brain barrier (BBB) under physiological flow in vitro.

View Article and Find Full Text PDF

Peripheral central nervous system (CNS)-infiltrating lymphocytes are a hallmark of relapsing-remitting multiple sclerosis. Tissue-resident memory T cells (T) not only populate the healthy CNS parenchyma but also are suspected to contribute to multiple sclerosis pathology. Because cerebrospinal fluid (CSF), unlike CNS parenchyma, is accessible for diagnostics, we evaluated whether human CSF, apart from infiltrating cells, also contains T cells and CNS-resident myeloid cells draining from the parenchyma or border tissues.

View Article and Find Full Text PDF